TY - JOUR
T1 - Immunotherapy for non-small cell lung cancer
T2 - Are we on the cusp of a new era?
AU - Waqar, Saiama N.
AU - Morgensztern, Daniel
N1 - Publisher Copyright:
© 2015 Informa UK, Ltd.
PY - 2015/8/1
Y1 - 2015/8/1
N2 - In this editorial, we highlight the exciting advances in immunotherapy for the treatment of non-small cell lung cancer, with nivolumab being the first immunotherapeutic agent to be approved by the US FDA for the treatment of squamous lung cancer and several other promising immune checkpoint inhibitors currently being evaluated in clinical trials. The next step is to understand the mechanisms of resistance and develop rational combinations in an attempt to further improve the responses and survival in lung cancer.
AB - In this editorial, we highlight the exciting advances in immunotherapy for the treatment of non-small cell lung cancer, with nivolumab being the first immunotherapeutic agent to be approved by the US FDA for the treatment of squamous lung cancer and several other promising immune checkpoint inhibitors currently being evaluated in clinical trials. The next step is to understand the mechanisms of resistance and develop rational combinations in an attempt to further improve the responses and survival in lung cancer.
KW - PD-1
KW - PDL-1
KW - immunotherapy
KW - nivolumab
KW - non-small cell lung cancer
UR - http://www.scopus.com/inward/record.url?scp=84937203790&partnerID=8YFLogxK
U2 - 10.1586/1744666X.2015.1054374
DO - 10.1586/1744666X.2015.1054374
M3 - Review article
C2 - 26051156
AN - SCOPUS:84937203790
SN - 1744-666X
VL - 11
SP - 871
EP - 873
JO - Expert Review of Clinical Immunology
JF - Expert Review of Clinical Immunology
IS - 8
ER -